Runben Biotechnology Co., Ltd. (SHA:603193)

Runben Biotechnology Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	62.38	106.59	243.83	368.21	206.19	39.53
Short-Term Investments	-	77.95	1,340	-	-	-
Trading Asset Securities	1,324	1,249	19	8.24	56.24	42.17
Cash & Short-Term Investments	1,386	1,434	1,603	376.45	262.43	81.7
Cash Growth	947.10%	-10.57%	325.85%	43.45%	221.20%	130.74%
Accounts Receivable	21.44	13.59	4.82	1.19	2.34	2.78
Other Receivables	7.14	4.62	2.32	6	9.8	5.73
Receivables	28.58	18.22	7.14	7.2	12.15	8.51
Inventory	183.63	118.57	92.91	102.71	56.9	45.22
Other Current Assets	65.12	24.43	13.16	23.68	12.89	6.38
Total Current Assets	1,664	1,595	1,716	510.04	344.36	141.82
Property, Plant & Equipment	278.19	267.57	260.42	277.56	207.67	108.73
Other Intangible Assets	54.19	54.54	18.76	19.36	19.88	20.54
Long-Term Deferred Tax Assets	50.96	44.23	20.82	14.8	5.66	2.39
Long-Term Deferred Charges	1.22	1.26	1.41	-	-	-
Other Long-Term Assets	253.49	256.9	1.13	3.65	68.77	2.99
Total Assets	2,302	2,219	2,019	825.42	646.34	276.47
Accounts Payable	99.08	53.8	40.15	36.99	46.37	13.27
Accrued Expenses	10.44	32.16	26.21	24.43	11.41	5.98
Current Portion of Leases	1.38	1.37	1.95	2.51	2.4	-
Current Income Taxes Payable	46.87	26.29	15.47	18.28	5.29	0.63
Current Unearned Revenue	6.06	13.37	5.97	4.5	4.2	3.44
Other Current Liabilities	7.49	10.21	5.36	9.89	5.84	0.92
Total Current Liabilities	171.31	137.19	95.12	96.6	75.52	24.23
Long-Term Leases	1.06	1.42	2.04	5.39	7.91	-
Long-Term Unearned Revenue	4.27	0.01	0.01	0.27	1.13	2.05
Long-Term Deferred Tax Liabilities	0.27	0.27	0.44	0.57	0.14	0.05
Total Liabilities	176.92	138.88	97.61	102.83	84.69	26.33
Common Stock	404.59	404.59	404.59	343.9	343.9	103.07
Additional Paid-In Capital	1,015	1,015	1,015	102.59	101.69	117.28
Retained Earnings	704.87	660.67	502.12	276.09	116.05	29.79
Shareholders' Equity	2,125	2,080	1,921	722.59	561.65	250.14
Total Liabilities & Equity	2,302	2,219	2,019	825.42	646.34	276.47
Total Debt	2.44	2.78	4	7.91	10.31	-
Net Cash (Debt)	1,384	1,431	1,599	368.54	252.12	81.7
Net Cash Growth	975.89%	-10.52%	333.90%	46.18%	208.59%	130.74%
Net Cash Per Share	3.40	3.53	4.53	1.08	0.75	0.27
Filing Date Shares Outstanding	404.59	404.59	404.59	404.59	343.9	305.52
Total Common Shares Outstanding	404.59	404.59	404.59	343.9	343.9	305.52
Working Capital	1,492	1,458	1,621	413.44	268.84	117.59
Book Value Per Share	5.25	5.14	4.75	2.10	1.63	0.82
Tangible Book Value	2,070	2,026	1,903	703.22	541.76	229.6
Tangible Book Value Per Share	5.12	5.01	4.70	2.04	1.58	0.75
Buildings	-	231.94	232.54	231.65	163.47	43.21
Machinery	-	96.7	87.77	79.06	57.22	29.25
Construction In Progress	-	18.07	1.82	5.76	7.17	59.01

Source: S&P Global Market Intelligence. Standard template. Financial Sources.